Pharmaceutical Executive March 20, 2025
DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
Sanofi has reached an agreement with Dren Bio to acquire DR-020, a CD20-directed bispecific antibody currently in early clinical trials for refractory B-cell-mediated autoimmune diseases, in a deal that could be valued at up to $1.9 billion.
Under the terms of the agreement, which is expected to close in the second quarter of 2025, Sanofi will make an upfront payment of $600 million to Dren Bio. The company may also receive up to $1.3 billion in additional payments upon achieving key development and launch milestones. Sanofi plans to finance the transaction with existing cash resources. Following the acquisition,...
Today's Sponsors
Today's Sponsor